Medicus Biosciences, LLC

Applied Materials, Inc.

Pilkington Barnes Hind, Inc.

Trivascular, Inc.

C.p. Medical Corporation

Other

Shifamed Holdings, LLC

Medical Biosciences LLC

Syed Hasan Askari

Yeon S Choi

George Horng

Hermann H Neidlinger

Shamouil Shamouilian

Robert G Whirley

Surinder S Bedi

Manoocher Birang

Tom Saul

Claudio Argento

Ananda H Kumar

Arnold Kholodenko

Kadthala Ramaya Narendrnath

Dennis Stanley Grimard

Alexander M Veytser

You Wang

Arindam Datta

John H Prince

Mohsen Salek

Allan Gleason

Liang-Guo Wang

Khushroo Gandhi

Jon T Clinton

Jacob Raquet

Paul YuJen Wan

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

Biocompatible hydrogel treatments for retinal detachment

Hydrogel compositions prepared from amine components and glycidyl ether components are provided which are biocompatible and suitable for use in vivo due, in part, to their excellent stability.

Non-degradable, low swelling, water soluble radiopaque hydrogel polymer

Provided herein are biocompatible hydrogel polymers capable of gelling in vivo comprising a therapeutic agent such as a protein or other biomolecule and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and releases the therapeutic agent at a target site, avoiding systemic exposure and achieving a controlled delivery.

Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules

An accommodating intraocular lens (AIOL) for implantation within a capsular bag of a patient's eye comprises first and second components coupled together to define an inner fluid chamber and an outer fluid chamber. The inner region of the AIOL provides optical power with one or more of the shaped fluid within the inner fluid chamber or the shape of the first or second components. A surface treatment or coating may be applied to one or more surfaces of the first and second components. The surface treatment is expected to decrease the roughness of the machined surfaces of the boundary surfaces of the first and second components, and thereby reduce the mass of water coalescing at such boundary surfaces. The disclosed surface treatments are also expected to increase the hydrophobicity (i.e., decrease the surface energy) of the corresponding surface(s), thereby decreasing the 'wettability' of these surfaces.

Surface treatments for accommodating intraocular lenses and associated methods and devices

Provided herein are methods of treating diseases of the lung in a mammal, including cancer of the lung, mesothelioma, emphysema, and bronchopleural fistula. The methods comprise delivering a biocompatible hydrogel polymer optionally comprising a therapeutic agent directly to a target site using a minimally invasive delivery device, wherein the biocompatible hydrogel polymer gels at the target site.

Methods for treating diseases of the lung

Provided herein are in vivo gelling pharmaceutical pre-formulations forming biocompatible hydrogel polymers that are polymerized in vivo and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and releases the therapeutic agent at a target site, avoiding systemic exposure.

In-vivo gelling pharmaceutical pre-formulation

Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease.

Solid polyglycol-based biocompatible pre-formulation

A chamber for processing a substrate comprises a support comprising a dielectric enveloping an electrode The electrode may be chargeable to electrostatically hold the substrate or may be chargeable to form an energized gas in the chamber to process the substrate A base is below the support and a compliant member is positioned between the support and the base The compliant member may be adapted to alleviate thermal stresses arising from a thermal expansion mismatch between the dielectric and the base

Support for supporting a substrate in a process chamber

The present invention provides a retaining ring having an resilient liner for protecting the substrate edge from being damaged during chemical mechanical polishing and a method for making the same. Retainers made of wear resistant ceramics, such as alumina, provide better overall performance, including wear resistance, and reduced particle formation than other retaining ring materials. By incorporating a resilient liner, such as an epoxy, on the inner surface of the wear resistant ring, the substrate edge is protected from damage that can be easily caused by the hard surface of the ceramic alone.

Retainers and non-abrasive liners used in chemical mechanical polishing

Growing community of inventors

San Jose, CA, United States of America

Syed Hasan Askari